These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2504598)

  • 1. Antimicrobial activity and interaction of pefloxacin and its principal metabolites. Collaborative Antimicrobial Susceptibility Testing Group.
    Jones RN
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):551-6. PubMed ID: 2504598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE; Wickerhoff-Minoggio T
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
    Debbia E; Schito GC; Nicoletti G; Speciale A
    Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicenter study of the activity of pefloxacin on bacteria isolated in a hospital milieu].
    Soussy CJ; Acar JF; Bergogne-Berezin E; Christol D; Courtieu AL; Duval J; Fleurette J; Lareng MB; Morel C; Thabaut A
    Rev Med Interne; 1986 Mar; 7(2):197-204. PubMed ID: 3459222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL; Jones RN
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome.
    Appelbaum PC; Spangler SK; Sollenberger L
    J Antimicrob Chemother; 1986 Dec; 18(6):675-9. PubMed ID: 3469178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.
    Vanhoof R; Hubrechts JM; Roebben E; Nyssen HJ; Nulens E; Leger J; De Schepper N
    Infection; 1986; 14(6):294-8. PubMed ID: 3546145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
    Soussy CJ; Deforges L; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.